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Introduction
Administration of oral nitrate (NO 3 -), in its various forms, increases the level of nitric oxide (NO) metabolites in blood. Its application to modulate physiology and alleviate cardiovascular dysfunction shows particular promise in certain clinical conditions and patient cohorts, including reduction of mean arterial pressure in hypertension [1, 2] , effective quiescencing of platelet activation/aggregation [3] , and reduce risk in conditions where tissue ischemia prevails [4] . However, it is the potential of oral NO 3 -to modify exercise/performance via elevation of plasma nitrite concentration ([NO 2 -] ) that has been applied across a range of human test systems, from the effects of walking distance in a sedentary population [5] to enhancing performance in elite athletes [6] .
There is a general consensus on the principal pathways and primary mechanisms involved in the conversion of oral NO 3 -to circulating NO 2 -and NO. However, there remains significant variation in the levels of NO metabolites attained in the plasma and it is presently not known which levels are sufficient to enhance physical performance in a particular setting. Most investigators (but not all) are aware of the many controllable factors that introduce variance and take measures to counter these (e.g.
cohort choice and dietary restriction). We must also acknowledge other, potentially less obvious sources of variation in our research designs or otherwise risk misinterpreting our performance findings.
Herein we discuss how the choice of NO 3 -source, route of administration and resulting pharmacokinetics might influence the outcome of physiological studies and potentially contribute to discrepancy in performance trials. There are but a few examples of detailed pharmacokinetic data on which the majority of researchers base their test protocol in different cohorts/settings. We compare and contrast the results of key publications with the aim of highlighting to this readership a consensus of our current understanding and critical considerations for those entering the field. Perhaps opportunity exists in exploiting these observations.
Nitrate (NO 3 -) source
The source of NO 3 -influences the concentration, bioavailability, subject compliance and route of administration. Foodstuffs contain varying concentrations of NO 3 - , with leafy vegetables and beetroot (BR) a relatively rich source [7] . The awareness and consumption of NO 3 -has been enhanced by the recent commercialisation of BR, chard and rhubarb concentrates in products such as Beet it® (James White Drinks) and Go+Nitrate® gel (Science in Sport). With a burgeoning awareness of the potential importance of NO 3 -in sport and exercise, an ever-increasing variety of NO 3 -fortified products are becoming commercialised, ranging from sport bars and lozenges to BR capsules. Importantly, NO 3 -salts (in solution or via capsule) are readily available for both oral and intravenous administration and ] ratio, as defined in Table 1 ) was relatively consistent (1.0-1.2) and is in keeping with the work of most using BR [11] [12] [13] [14] , but inconsistent with Webb et al hrs, and a plasma t½ of >6 hrs is found irrespective of KNO 3 dose (4 -24 mmol).
In addition, taken together there is good evidence that time to peak NO 3 -may depend on the source of NO 3 -, although there are notable exceptions [11] . In general, a KNO 3 solution/capsule and NO 3 -containing gel (SiS Go+Nitrate) appear to exhibit an earlier peak (~1hr) when compared with BR at a similar loading dose. Conversely, there is some evidence to indicate that the overall yield from BR may be higher in comparison to other NO 3 -sources such as swiss chard (SiS Go+Nitrate, based on area under curve analysis over 24 hrs, Figure 1 ). However, care must be taken in over-interpreting this early observation. It is entirely possible that different forms of nitrate delivery (whether gel, food, or liquid) may in itself dictate plasma pharmacokinetics. This can only be resolved by appropriate crossover studies in the same individuals.
Importantly, there is discrepancy in the level of plasma [NO 2 -] attained per unit amount of NO 3 -administered between groups (0.5 -2.5) and even within individual subjects over a prolonged period of time. Of those utilising a similar BR source, in one or two repeated tests there is an apparent split between those exhibiting high relative yield [12] [13] [14] and those finding significantly lower yield [3, 11] . In these examples, volume of NO 3 -administration does not appear to be the cause of the discrepancy, neither does this appear to be methodological (since all studies essentially use ozonebased chemiluminescence to measure plasma NO metabolites). ] which may be impractical unless pre-determined in that particular subject.
Individual versus Group Variation
This is difficult to interpret from grouped data expressed as mean±error. Certainly in our hands [13] there remains noticeable variation in both time to peak, and peak plasma [ . It is tempting to speculate this reflects mainly differences in dealing with and/or storing the plasma sample as we and others have demonstrated [15] . There is no observable trend to indicate higher baseline plasma levels influence the peak yield, but this remains to be tested directly. Figure 3 shows the scatter between measured plasma [NO The influence of NO 3 -supplementation on a wide range of exercise activities has been investigated, ranging from 500 m kayaking [24] to 50 miles cycling [25] , with predictably mixed results. While the majority of studies to date have assessed the influence of NO 3 -supplementation on continuous exercise, a few have considered possible effects on intermittent high-intensity exercise tests which are reflective of the pattern of exertion during team sports. While, once again, the results of these studies have been mixed, owing at least in part to differences in dosing and duration of supplementation, there is evidence that NO 3 -can be ergogenic in such activities [10] . With such discrepancies in the efficacy of NO 3 -supplementation on exercise performance, several activity-specific factors need to be considered.
Environmental conditions
Conditions of low O 2 availability would be expected to lower NO synthase (NOS) function and therefore to potentially augment NO production via the reduction of NO 2 -. Consistent with this, it appears that ambient O 2 influences the ability of NO 3 -ingestion to enhance exercise performance. In hypoxia, intramuscular perturbation of phosphate-linked substrates and metabolites is blunted when exercise is preceded by NO 3 -ingestion [26] and cycle time trial [13] and incremental exercise [27] performance in hypoxia is improved following NO 3 -supplementation. The recovery of muscle phosphocreatine concentration, an index of oxidative capacity, is enhanced in hypoxia but not normoxia following NO 3 -supplementation and this effect appears to be related to improved muscle oxygenation [28] . To date, improved exercise performance following NO 3 -supplementation has been more consistently observed in hypoxia compared to normoxia, and environmental conditions are therefore another factor worthy of consideration when assessing differences between studies.
Fitness status
Another important consideration is the fitness/training status of the participants in NO 3 -supplementation studies. Subjects who are aerobically trained, and especially elite endurance athletes, will have experienced numerous adaptations that may limit the possible benefits of NO 3 -supplementation. These adaptations include: greater NOS activity; greater muscle oxygenation owing to greater muscle capillary density; mitochondrial proliferation and possibly improved mitochondrial efficiency; higher baseline plasma [NO 2 -]; and lower proportion of type II muscle fibres. Conversely, subjects with compromised cardiovascular and skeletal muscle systems often show peripheral tissue maladaptations to these chronic disease conditions which may include capillary density rarefaction, a reduction in mitochondrial number and efficiency, and a higher proportion of type II muscle fibres.
Numerous exercise performance studies in disease states such as peripheral arterial disease [29] , chronic heart failure [30] and pulmonary diseases [31] are starting to emerge.
Although there is evidence that the exercise performance of elite athletes can be improved by NO 3 -supplementation [23] , it does appear that better trained athletes benefit less compared to lesser trained individuals, at least when a similar NO 3 -dose is ingested. It is important to note, however, that it is possible that elite athletes will respond better to NO 3 -supplementation with larger doses or more protracted supplementation regimens. Irrespective of training status, it has been suggested that there may be 'responders' and 'non-responders' to NO 3 -supplementation [24] , and this also may explain 
Final perspectives
We have selectively drawn on the work of several groups to highlight important similarity but also noticeable discordance in results. These key studies were typically undertaken using a back-to-basics pharmacological approach, and it seems worthwhile for investigators comparing new cohorts, exercise programs or patients to at least first ensure that the axis of NO 3 --NO 2 --NO metabolism is as expected in their particular cohort or model. It will also be critical to first establish whether individual variation could be greater than the effect being tested. It is unlikely that we will be able to advance our understanding and significantly exploit potentially ergogenic and therapeutic properties of oral NO 3 -supplementation until these processes are elucidated. 
